Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Casgevy (exa-cel)
Pharma
With 64 centers activated, bluebird is ready to grow Lyfgenia
Bluebird has started its first patient on its sickle cell disease gene therapy Lyfgenia. And with 64 treatment centers active, there's room to grow.
Kevin Dunleavy
May 9, 2024 1:40pm
Vertex's Casgevy launch progresses as CF drugs post solid growth
May 7, 2024 11:23am
Reshma Kewalramani joins exclusive club, topping $20M in pay
Apr 8, 2024 8:26am
NICE rejects Vertex, CRISPR's Casgevy, asks for more data
Mar 14, 2024 11:24am
Michigan Medicaid signs deal with bluebird for SCD gene therapy
Mar 11, 2024 11:00am
Vertex's sales of Trikafta hit $8.9B thanks to label expansion
Feb 6, 2024 12:39pm